ATA Differentiated Thyroid Cancer Derivative

Differentiated Thyroid Cancer Guidelines

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/706038

Contents of this Issue

Navigation

Page 1 of 11

Thyrogen® (thyrotropin alfa for injection) 0.9 mg/mL INDICATIONS AND USAGE • Thyrogen ® is a thyroid stimulating hormone indicated for: Diagnostic: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Limitations of Use: • Thyrogen-stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal. • Even when Thyrogen-Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease. • Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable. Ablation: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer. Limitations of Use: • The effect of Thyrogen on long term thyroid cancer outcomes has not been determined. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS • There have been reports of death in non-thyroidectomized patients and in patients with distant metastatic thyroid cancer in which events leading to death occurred within 24 hours after administration of Thyrogen. • There are post marketing reports of stroke in young women with risk factors for stroke, and neurological findings suggestive of stroke (e.g., unilateral weakness) occurring within 72 hours of Thyrogen administration in patients without known central nervous system metastases.

Articles in this issue

view archives of ATA Differentiated Thyroid Cancer Derivative - Differentiated Thyroid Cancer Guidelines